Over a hundred former Republican officials have written an open letter supporting Harris: Trump is not suitable to regain the White House.
① These Republican officials have served in institutions such as the White House, Department of Defense, Department of Treasury, Department of State, Department of Justice, Department of Homeland Security, and Congress; ② These officials have expressed that although there may be policy differences with Harris, these concerns seem insignificant compared to the "chaos and unethical behavior" exhibited by Trump.
Comparing UnitedHealth Group With Industry Competitors In Health Care Providers & Services Industry
Amedisys Sale to UnitedHealth Unlikely to Be Done Until at Least End of November
Merck's Keytruda Label Expanded in the U.S. for Mesothelioma
Looking Into Eli Lilly's Recent Short Interest
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
Unpacking the Latest Options Trading Trends in Eli Lilly
BioNTech Raised to Buy at Jefferies on New Cancer Drug
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Senseonics Eversense 365 Glucose Monitor Cleared in the U.S.
BeyondSpring Plinabulin, Merck Keytruda Combo Shows Promise in NSCLC
What the Options Market Tells Us About UnitedHealth Group
A Closer Look at 8 Analyst Recommendations For Merck & Co
CG Oncology Surges 7%; Seen Benefitting From J&J Bladder Cancer Asset Data
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target
Merck & Co Analyst Ratings
Eli Lilly Analyst Ratings
Moderna Was Most Shorted S&P 500 Healthcare Stock in August for Second Consecutive Month
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges